Vasopressor Weaning

Cross-source consensus on Vasopressor Weaning from 1 sources and 5 claims.

1 sources · 5 claims

Benefits

Prior studies of midodrine for vasopressor weaning in critically ill patients have produced inconsistent results. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
The existing evidence justifies a definitive pragmatic trial but does not establish benefit. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
Studies in postoperative and surgical ICU populations suggested midodrine may accelerate vasopressor liberation, but findings were heterogeneous. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
A systematic review and meta-analysis found midodrine was associated with shorter IV vasopressor duration and lower hospital mortality. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial
A 32-patient pilot randomized trial found nominal reductions in vasopressor dose and duration, central venous catheter duration, and ICU length of stay in the midodrine arm. — Midodrine for Sepsis Treatment and Early Vasopressor Weaning (MID-STEP): protocol for a pragmatic randomised clinical trial